Projected Growth of the Global Stem Cell Therapy Market to Reach $104.37 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the stem cell therapy market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Stem Cell Therapy Market By The End Of 2029?

The blood cancer drugs market has experienced substantial expansion over recent years. This market is projected to expand from $74.69 billion in 2024 to $79.6 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%. Historical growth in this sector is largely due to progress in research and development, the increasing elderly demographic, improved public awareness leading to earlier diagnoses, and favorable regulatory approvals.

The blood cancer drugs market is projected to experience substantial expansion over the upcoming years. This market is set to reach $104.37 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is primarily driven by factors such as the rising prevalence of diseases, the emergence of new markets, and the availability of supportive care. Key trends characterizing this period include increased investments in research and development, the adoption of combination therapies, better biomarker identification, breakthroughs in immunotherapy, and the development of personalized medicine approaches.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Which Business Drivers Are Underpinning The Growth Of The Stem Cell Therapy Market?

The blood cancer drugs market is being stimulated by the increasing global rates of mortality and prevalence of blood cancer cases. Various types of blood cancers, such as lymphoma, leukemia, myeloma, and others, present different risk factors; some can be managed or prevented through drug therapies, while others may unfortunately result in death. For instance, in November 2022, a report by the Bristol-Myers Squibb Company projected that over 1.85 million new blood cancer cases are expected to be diagnosed globally by 2040, with 918,872 cases attributed to lymphoma, 656,345 to leukemia, and 275,047 to myeloma. Additionally, the report estimated that the approximate number of deaths worldwide due to blood cancer in 2040 will reach 1,100,000.

What Are The Principal Segment Types In The Stem Cell Therapy Market?

The blood cancer drugs market covered in this report is segmented –

1) By Blood Cancer Type: Leukemia, Lymphoma

2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs

3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

Subsegments:

1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia

2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

How Are Industry Trends Steering The Expansion Of The Stem Cell Therapy Market?

Key companies involved in the blood cancer drugs market are concentrating on developing new medications and actively pursuing FDA approval to achieve a competitive position. FDA approval for drugs denotes the formal authorization provided by the United States Food and Drug Administration, allowing a pharmaceutical product to be legally marketed and sold within the United States. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, received FDA approval for its inaugural and exclusive CAR T-cell therapy for adults living with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval permits its use in patients who have previously undergone at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi exhibited a 20% complete response rate and a median duration of response of 35.3 months among those who responded.

Which Companies Are Contributing Significantly To The Stem Cell Therapy Market Growth?

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Which Region Offers The Most Opportunity For Stem Cell Therapy Market Expansion?

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp

Browse Through More Reports Similar to the Global Stem Cell Therapy Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795